Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-arm, Open-label, Early-stage Clinical Study of UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

NCT06279026 is registered in ClinicalTrials.gov with PersonGen BioTherapeutics (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT06279026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06279026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-arm, Open-label, Early-stage Clinical Study of UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
Lead sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase
Not applicable
Overall status
Recruiting
Start date
April 1, 2024
Completion date
July 1, 2027
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma